---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-109389"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2022-10-17T23:59:59+00:00"
generated_at: "2026-06-23T03:19:31.594280+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Hepion reports $71.7M cash; progressing Phase 2 NASH and upcoming HCC trials

## Summary
- Cash and equivalents of $71.7M as of June 30, 2022; 76.2M common shares outstanding.
- Rencofilstat Phase 2b ASCEND-NASH (biopsy) and Phase 2 ALTITUDE-NASH (liver function) trials underway.
- Upcoming Phase 2a HCC trial for rencofilstat in advanced hepatocellular carcinoma.
- AI-POWR platform used to identify responders and companion diagnostic panel.
- Rencofilstat shown safe/tolerated in >200 subjects; Phase 2a AMBITION study met primary endpoints.

## SEC filing metadata
- accession: 0001104659-22-109389
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2022-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000110465922109389/0001104659-22-109389-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000110465922109389/tm2228403d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-109389
- JSON: https://secwatch.observer/filing/0001104659-22-109389.json
- Plain text: https://secwatch.observer/filing/0001104659-22-109389.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.